Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro
Matthew H. Raymonda, Jessica H. Ciesla, Morgan Monaghan, Justin Leach, Gloria Asantewaa, Leonid Smorodintsev-Schiller, Michael M. Lutz, Xenia Schafer, Toru Takimoto, Stephen Dewhurst, J. Munger, Isaac S. Harris
Topics & Concepts
LapatinibBiologyVirologyViral replicationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antiviral drugVirusProfiling (computer programming)CrizotinibPharmacologyCoronavirus disease 2019 (COVID-19)Computational biologyCancerMedicineInfectious disease (medical specialty)Breast cancerDiseaseGeneticsOncologyComputer sciencePathologyMalignant pleural effusionOperating systemLung cancerTrastuzumabSARS-CoV-2 and COVID-19 Researchinterferon and immune responsesPlant Virus Research Studies